Neurocrine Biosciences

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The firm's product includes INGREZZA. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Neurocrine Biosciences reports strong Q4 performance and eyes growth

Neurocrine Biosciences delivered strong performance in Q4 2022, with robust INGREZZA sales and a positive outlook for 2023, supported by significant investments in SG&A and R&D.
The company's focus on expanding into long-term care, advancing pipeline assets, and collaborations for innovative treatments positions it well for growth and addressing unmet needs.
While facing challenges in managing increased spending and market dynamics, Neurocrine remains optimistic about opportunities in expanding treatment reach, market penetration, and advancing clinical programs.

Neurocrine Biosciences reports strong Q1 performance and eyes international expansion

Neurocrine Biosciences had a strong Q1 performance with record sales, upcoming milestones, and disciplined expense management.
The company faces challenges in certain therapeutic categories but is optimistic about addressing unmet needs and expanding internationally.
Opportunities lie in innovative science, market positioning, and portfolio expansion, positioning Neurocrine for future growth.
Addressing concerns around drug interactions, dosing strategies, and trial risks will be crucial for maintaining clinical success and patient safety.

Neurocrine Biosciences excels in Q2, eyes growth opportunities ahead

Neurocrine Biosciences shows strong financial performance and growth prospects.
Focus on INGREZZA's persistency and pipeline advancements drives optimism.
Challenges include market dynamics and clinical trial complexities.
Opportunities lie in new indications, long-term care expansion, and telemedicine.

Neurocrine Biosciences excels in Q3, eyes growth in LTC segment

Neurocrine Biosciences delivered a strong Q3 performance with robust sales, positive regulatory developments, and promising pipeline advancements.
The company's focus on expanding indications, exploring combination therapies, and addressing market opportunities positions it for future growth.
While facing challenges in market evaluation and competition, Neurocrine Biosciences has opportunities to leverage its strengths and drive innovation.
Investors can look forward to upcoming events like the Analyst Day and R&D Day for deeper insights into the company's strategic direction and growth potential.

Neurocrine Biosciences excels in 2023, eyes Crinecerfont launch success

Neurocrine Biosciences had a strong 2023 with notable achievements in sales growth and pipeline advancements. While facing challenges in market dynamics and pricing negotiations, the company is well-positioned to leverage opportunities in upcoming launches and strategic growth initiatives.

Neurocrine Biosciences excels in Q1 with strong sales and pipeline advancements

Neurocrine Biosciences delivered a strong performance in Q1 2024, driven by robust INGREZZA sales, promising Phase II results for NBI-845, and advancements in Crinecerfont development.
The company's strengths lie in its diverse pipeline, financial stability, and strategic focus on chronic therapy and tolerability, positioning it for future growth and innovation.
While facing challenges in dosing optimization and revenue management, Neurocrine has opportunities to leverage its pipeline, explore new treatments, and differentiate its offerings in the market.

Neurocrine Biosciences excels in Q3, poised for growth ahead

Neurocrine Biosciences showcased robust performance in Q3, with strong INGREZZA sales and pipeline success, positioning for future growth.
The company's strengths lie in its expanded sales team, leadership quality, and commitment to innovation and value creation for shareholders.
Challenges include potential payer reimbursement issues, FDA interactions for Phase III strategy, and competitive pressures in the market.
Opportunities abound with upcoming regulatory approvals, pipeline advancements, and targeted commercial strategies for new product launches.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Owens-Illinois

NEW YORK, March 24, 2021 /PRNewswire/ -- Neurocrine Biosciences Inc. (NASD:NBIX) will replace O-I Glass Inc. (NYSE:OI) in the S&P MidCap 400, and O-I Glass will replace HMS Holdings Corp (NASD:HMSY) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, March 30. Veritas Capital is acquiring HMS Holding in a deal expected to be completed soon pending final conditions.

Neurocrine Biosciences Set to Join S&P MidCap 400; O-I Glass to Join S&P SmallCap 600

SAN DIEGO, March 20, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present additional positive data from its Phase II CAHlibrate study of crinecerfont, an investigational, oral, non-steroidal corticotropin-releasing factor type 1 (CRF1) receptor antagonist for the potential treatment of classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD), at ENDO 2021, the Endocrine Society's annual meeting, on March 20–23, 2021. These new analyses, based on data from seven male subjects with classic CAH receiving crinecerfont, demonstrate dose-dependent decreases in androstenedione (A4), a key marker of CAH control and precursor to testosterone, with similar dose-dependent decreases in the A4 to testosterone ratio.

Neurocrine Biosciences to Present New Data Analyses for Crinecerfont in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2021

Blackrock Inc

Citigroup

Goldman Sachs

Medtronic

Just like that, we are less than two weeks from the end of the first quarter. While it has been a very positive one for investors, the rise in interest rates has brought in much higher volatility and has really pressured technology stocks.

5 Analyst Favorite Stocks to Buy for Q2 That Could Be Huge Winners

Centene

Sarepta Therapeutics

Out Of Favor Health Care Stocks includes healthcare and pharma names that have done reasonably well financially in recent years, although their stock prices have lagged, due to Covid-19 related disruptions in the healthcare industry or due to some setbacks in their development pipelines.

Centene, Neurocrine, Sarepta: Will These Out Of Favor Healthcare Stocks Outperform?

A few months back we discussed why Neurocrine Biosciences stock, a biotech company that develops treatments for neurological and endocrine-related diseases and disorders, looks oversold at $90 levels. Between mid-December 2020 to mid-February 2021, NBIX stock rallied over 30% from $90 to $120.

The Sell-off In Neurocrine Stock Post Luvadaxistat Failure Is Unwarranted

SAN DIEGO, March 9, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Oppenheimer 31st Annual Healthcare Conference at 4:30 p.m. Eastern Time on Tuesday Mar. 16, 2021.

Neurocrine Biosciences to Present at the Oppenheimer 31st Annual Healthcare Conference

Takeda Pharmaceutical

Neurocrine Biosciences Inc (NASDAQ: NBIX) announces topline data from Phase 2 INTERACT study evaluating luvadaxistat (NBI-1065844/TAK-831) for the treatment of negative symptoms and cognitive impairment associated with schizophrenia. Luvadaxistat is an oral, selective inhibitor with a high binding affinity to d-amino acid oxidase.

Neurocrine/Takeda's Luvadaxistat Fails To Improve Schizophrenia Symptom Severity

SAN DIEGO, March 2, 2021 /PRNewswire/ -- Neurocrine Biosciences (Nasdaq: NBIX) today announced that investigational drug luvadaxistat (NBI-1065844/TAK-831) did not meet its primary endpoint in the Phase II INTERACT study in adults with negative symptoms of schizophrenia, as measured by...

Neurocrine Biosciences Announces Top-Line Results from Phase II INTERACT Study Evaluating Luvadaxistat (NBI-1065844) for the Treatment of Negative Symptoms and Cognitive Impairment Associated with Schizophrenia (CIAS)

Vertex, Inc.

Our theme of Out Of Favor Health Care Stocks includes companies that have robust revenue growth and improving margins, and yet have not rallied much over the last year or so, due to Covid-19 related disruptions in the healthcare industry or due to some setbacks in their development pipelines.

Sarepta, Vertex & Neurocrine: Out Of Favor Healthcare Stocks To Watch

Neurocrine had already informed investors about weak fourth quarter Ingrezza sales, but AbbVie sales of Orilissa and Oriahnn were weak again, and Ongentys missed expectations as well. Management is upping its marketing spend, likely focusing on getting docs more comfortable with prescribing Ingrezza and Ongentys through telemedicine.

Neurocrine Biosciences Upping Marketing Spend To Support Its Platform

Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q4 2020 Results - Earnings Call Transcript

Neurocrine (NBIX) delivered earnings and revenue surprises of 506.78% and -4.81%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Neurocrine Biosciences (NBIX) Q4 Earnings Top Estimates

Shares of Neurocrine Biosciences (NASDAQ:NBIX) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 13.33% year over year to $0.91, which beat the estimate of $0.54.

Recap: Neurocrine Biosciences Q4 Earnings

SAN DIEGO, Feb. 4, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth quarter and full-year ended December 31, 2020 and provided full-year 2021 financial expense guidance. "In 2020, we served more patients with tardive...

Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results

Neurocrine has chosen to terminate development of NBIb-1817, the gene therapy for Parkinson's it acquired through its partnership with Voyager.

Neurocrine Sheds Its Parkinson's Gene Therapy Program, While The Street Waits For Ingrezza Reacceleration

SAN DIEGO, Jan. 20, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report fourth quarter and year-end 2020 financial results after the Nasdaq market closes on Thursday, Feb. 4, 2021. Neurocrine will then host a conference call and webcast to...

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2020 Financial Results

Ionis Pharma

Our theme of Out Of Favor Health Care Stocks includes health care stocks that have witnessed strong Revenue growth and improving fundamentals over the last few years but have underperformed in 2020, on account of clinical setbacks or due to Covid-19 related disruptions of the health care industry.

Neurocrine, Ionis, Vertex: Underperforming Healthcare Stocks Poised To Recover

SAN DIEGO, Jan. 8, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today provided an update on its business performance, including preliminary net product and inventory adjusted sales results of INGREZZA® (valbenazine) for 2020, and key commercial and clinical development...

Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2020 Net Product Sales Results and 2021 Program Milestones

SAN DIEGO, Jan. 4, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 39th Annual J.P. Morgan Healthcare Conference at 2:00 p.m. Eastern Time on Monday Jan. 11, 2021. Kevin Gorman, Chief Executive Officer, will present at the conference. The live...

Neurocrine Biosciences to Present at the 39th Annual J.P. Morgan Healthcare Conference

ACADIA Pharma

uniQure

Vertex Pharmaceuticals

Zogenix

After an incredibly wild and wooly year for investors, many across Wall Street are cautiously optimistic for 2021.

5 Top Biotech Stocks to Buy for 2021 With Massive Upside Potential

Neurocrine Biosciences stock, a biotech company that develops treatments for neurological and endocrine-related diseases and disorders, has more room for growth in the near term. NBIX stock is up just 14% off the recent bottom, significantly underperforming the S&P which moved 64% since its March.

Neurocrine Stock Looks Attractive In the Wake Of A 30% Correction

Neurocrine Biosciences reported disappointing sales of Ingrezza, as disruptions to clinical practice caused by COVID-19 have impacted new prescriptions, refills, and patient compliance. If COVID-19 is the true source of Ingrezza headwinds, quarterly sales growth could be under pressure through at least mid-2021.

Neurocrine Biosciences Hit By Multiple Setbacks

Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q3 2020 Results - Earnings Call Transcript

Neurocrine (NBIX) delivered earnings and revenue surprises of -663.64% and -8.31%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Neurocrine Biosciences (NBIX) Reports Q3 Loss, Lags Revenue Estimates

Shares of Neurocrine Biosciences (NASDAQ:NBIX) decreased 13.34% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 7.78% year over year to $0.97, which beat the estimate of ($0.06).

News for Neurocrine Biosciences Stock (NBIX)